NCT06355245 MEDECA - Markers in Early Detection of Cancer
| NCT ID | NCT06355245 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Danderyd Hospital |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2018-03-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2018-03-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Early diagnosis of cancer is key for improving patient outcomes, but cancers are difficult to diagnose if patients present with unspecific symptoms. The principal objective of the MEDECA (Markers in Early Detection of Cancer) study is to identify a multi-analyte blood test that can detect and map occult cancer within a mixed population of patients presenting with serious but unspecific symptoms. The study will include 1500 patients referred to the Diagnostic Center at Danderyd Hospital (DC DS), a multidisciplinary diagnostic center referral pathway for patients with radiological findings suggestive of metastasis without known primary tumor or suspicion of serious but unspecific symptoms. Blood samples are collected prior to a standardized and extensive cancer diagnostic work-up, including an expanded panel of biochemical analyses and extensive imaging such as computed tomography or magnetic resonance investigations. In collaboration with world-leading international scientists, the blood samples will be analyzed for a panel of novel and established blood biomarkers predictive of an underlying cancer, including markers of neutrophil extracellular traps, circulating tumor DNA, platelet mRNA profiling, affinity-based proteomics and nuclear magnetic resonance metabolomics. The diagnostic accuracy of the blood biomarkers with respect to cancer detection during the diagnostic work-up will be analyzed through machine learning.
Eligibility Criteria
Inclusion Criteria: \- Age above 18 years One or more of the following symptoms/clinical signs: * General malaise * Severe tiredness * Unintentional weight loss * Fever of unknown cause * Uncharacteristic pain for \>4 weeks * Abnormal laboratory tests (e.g., anemia, elevated alkaline phosphatase levels, erythrocyte sedimentation rate (ESR), calcium etc.) * Diffuse pain without explanation * Marked increase in drug usage * Increasing health service seeking behavior * Radiological findings suggestive of metastasis without known primary tumor or suspicion Exclusion Criteria: * Unwillingness to participate in the study * Age below 18 years
Contact & Investigator
Charlotte Thålin, M.D., Ph.D
PRINCIPAL INVESTIGATOR
Danderyd Hospital Karolinska Institutet
Frequently Asked Questions
Who can join the NCT06355245 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06355245 currently recruiting?
Yes, NCT06355245 is actively recruiting participants. Contact the research team at charlotte.thalin@regionstockholm.se for enrollment information.
Where is the NCT06355245 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT06355245 clinical trial?
NCT06355245 is sponsored by Danderyd Hospital. The principal investigator is Charlotte Thålin, M.D., Ph.D at Danderyd Hospital Karolinska Institutet. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.